• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Exploring Results from CAPItello-291 Trial

Opinion
Video

William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.

  1. In November 2023, capivasertib received FDA approval for use in advanced hormone receptor-positive breast cancer based on the results from the CAPItello-291 phase III trial. How has capivasertib been integrated into the NCCN guidelines for breast cancer?
    1. What are your thoughts on sequencing of capivasertib use in the management of HR+ breast cancer?
  2. How does capivasertib compare to other PI3K pathway inhibitors alpelisib and inavolisib from safety and efficacy standpoints?
Related Videos
1 expert in this video
5 experts are featured in this series
1 expert in this video
5 experts are featured in this series
Dr Brian Slomovitz
Related Content
men's health month graphic | Image Credit: Hrida-stock.adobe.com

Men’s Health Month 2025: Spotlight on Prostate Cancer, Lifelong Health

June 3rd 2025
Article

Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health outcomes.

Read More

managed care cast logo

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

December 23rd 2024
Podcast

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Listen

Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease

Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease

June 3rd 2025
Article

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

Read More

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

December 17th 2024
Podcast

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Listen

The authors emphasized the need for further research into improving the diagnostic performance of both blood- and stool-based tests, particularly to enhance early lesion detection. | Image credit: SewcreamStudio - stock.adobe.com

FIT Outperforms Blood-Based cfDNA Test in Detecting Precancerous Colorectal Lesions

May 31st 2025
Article

Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal lesions, a comparative study found.

Read More

osteoporosis | Image Credit: reineg-stock.adob.ecom

Combining Bone Health, Function Scores Refines MG Fracture Prediction

May 30th 2025
Article

Combining FRAX and MG-ADL assessments enhances fracture risk prediction in patients with myasthenia gravis (MG), guiding targeted interventions for better outcomes.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.